KHR‑001
Duchenne Muscular Dystrophy
PreclinicalActive
Key Facts
About KAHR Medical
Israeli biotech delivering CRISPR‑derived gene‑editing and mRNA therapeutics for rare diseases and oncology.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy Drugs
| Drug | Company | Phase |
|---|---|---|
| MyoPAXon | Myogenica | Phase 1 |
| DMD Gene Therapy | Kinea Bio | Pre-clinical |
| NS-051/NCNP-04 | NS Pharma | Phase 1/2 |
| UCT-MSC + Biomaterials | Vitti Labs | Phase 2 |
| Myosana Platform for DMD | Myosana Therapeutics | Pre-clinical |
| PEPR-124 (RT-001) | Peptris Technologies Private | Phase 2-ready |
| DMD Genetic Screening Panel | Nanodigmbio | Commercial |
| PF-06939926 | Pfizer | Phase 3 |